Advertisement

Topics

Celgene Corporation and Agios Pharmaceuticals, Inc. Company Profile

10:56 EDT 22nd July 2018 | BioPortfolio


News Articles [1249 Associated News Articles listed on BioPortfolio]

FDA Grants Approval of Agios’ Pharmaceuticals’ TIBSOVO®

Agios Pharmaceuticals (NASDAQ:AGIO) has announced that TIBSOVO was granted approval from the US Food and Drug Administration (FDA) for treatment of adult patients with relapsed or refractory acute mye...

Agios, CStone collaborate on ivosidenib R&D

Agios Pharmaceuticals entered into a licensing deal with CStone Pharmaceuticals for the development and commercialization of  -More- 

Agios' AML therapy accepted under priority review by FDA

Agios Pharmaceuticals' new-drug application for ivosidenib, which is being developed as a treatment for patients with isocitr -More- 

FDA approves Agios Pharmaceuticals leukemia drug

Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

Agios Pharmaceuticals leukemia drug gets U.S. approval

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

Celgene im Übernahmefieber: Darum passt die BB-Biotech-Beteiligung Agios ins Beuteschema

Mit gleich zwei größeren Akquisitionen hat Celgene vor Kurzem die eigene Pipeline gestärkt. Doch der Übernahmehunger der Biotech-Firma ist keineswegs gestillt: Wie der Finanzvorstand im Rahmen der...

Agios Pharmaceuticals Scores FDA Approval For Tibsovo, Second AML Drug Win in Less Than a Year

Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a ...

Celgene, Agios Drug Enasidenib Among New Filings At EMA

Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation...   

PubMed Articles [135 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

Impact of Pharmaceuticals on the Environment: Risk Assessment Using QSAR Modeling Approach.

An extensive use of pharmaceuticals and the widespread practices of their erroneous disposal measures have made these products contaminants of emerging concern (CEC). Especially, active pharmaceutical...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Clinical Trials [229 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1514 Associated Companies listed on BioPortfolio]

Agios Pharmaceuticals, Inc.

Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Agios has ...

Celgene Corporation and Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals , Inc.

Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadersh...

Agios Pharmaceuticals

Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism. To suppor...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

More Information about "Celgene Corporation and Agios Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Celgene Corporation and Agios Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Celgene Corporation and Agios Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Celgene Corporation and Agios Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celgene Corporation and Agios Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Celgene Corporation and Agios Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record